Drugs for Pain: A Clarification
Selective COX-2 Inhibitors and Bleeding Risk: An Additional Note - The Medical Letter article on Drugs for Pain (August 21, 2000) stated that the selective COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) do not inhibit platelet aggregation or bleeding time. Perhaps we should have added, as we did in discussing use of these drugs in rheumatoid arthritis (July 10, 2000), that both celecoxib and rofecoxib, if given with warfarin (Coumadin, and others), increase INR and prothrombin time values and may increase the risk of bleeding.
This article has been freely provided.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Drugs for Pain: A Clarification
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1087
Article Code: 1087b
Date: September 18, 2000
Volume: 42
Pages: 83-92
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1087
Article Code: 1087b
Date: September 18, 2000
Volume: 42
Pages: 83-92
This article is not available for purchase.
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.